MedTrace Logo

Comparative Study of Prophylactic Agent for Venous Thromboembolism After Total Knee Arthroplasty

NCT02271399 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2016-02-19

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy of two prophylactic agent(aspirin 300mg/day and rivaroxaban 10mg/day) for venous thromboembolism after total knee arthroplasty.

Conditions

  • Venous Thromboembolism

Interventions

DRUG

acetylsalicylic acid

300 mg aspirin(acetylsalicylic acid, AA, Bayer)/day was given orally for 10 days postoperatively.

DRUG

rivaroxaban

xarelto 10mg(rivaroxaban, AA, Bayer)/day was given orally for 10 days postoperatively

Sponsors & Collaborators

  • Hanyang University Seoul Hospital

    lead OTHER

Principal Investigators

  • Choonghyoek Choi · Hanyang University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2016-01-31
Completion
2016-02-29

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02271399 on ClinicalTrials.gov